UniSa - IRIS Institutional Research Information System

PERSICO, Marcello
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 13.562
NA - Nord America 8.564
EU - Europa 2.806
SA - Sud America 778
AF - Africa 100
OC - Oceania 16
Continente sconosciuto - Info sul continente non disponibili 8
Totale 25.834
Salva come PNG Salva come JPEG
Nazione #
HK - Hong Kong 9.659
US - Stati Uniti d'America 8.408
SG - Singapore 1.764
CN - Cina 1.048
BR - Brasile 654
UA - Ucraina 634
IT - Italia 595
RU - Federazione Russa 420
VN - Vietnam 415
DE - Germania 324
IE - Irlanda 237
KR - Corea 224
FI - Finlandia 174
TR - Turchia 160
SE - Svezia 122
CA - Canada 101
GB - Regno Unito 76
IN - India 56
JP - Giappone 47
AR - Argentina 46
MX - Messico 37
ZA - Sudafrica 35
AT - Austria 33
BD - Bangladesh 32
FR - Francia 31
NL - Olanda 29
DK - Danimarca 26
ES - Italia 26
EC - Ecuador 25
ID - Indonesia 25
PL - Polonia 21
IQ - Iraq 19
TW - Taiwan 15
VE - Venezuela 15
AU - Australia 11
CO - Colombia 11
MA - Marocco 11
PK - Pakistan 11
LT - Lituania 10
CZ - Repubblica Ceca 9
DZ - Algeria 9
PY - Paraguay 9
EG - Egitto 8
UZ - Uzbekistan 8
AE - Emirati Arabi Uniti 7
PE - Perù 7
PS - Palestinian Territory 7
TN - Tunisia 7
EU - Europa 6
SA - Arabia Saudita 6
AZ - Azerbaigian 5
BE - Belgio 5
CH - Svizzera 5
JO - Giordania 5
KE - Kenya 5
KZ - Kazakistan 5
MY - Malesia 5
AL - Albania 4
DO - Repubblica Dominicana 4
HN - Honduras 4
IL - Israele 4
NP - Nepal 4
NZ - Nuova Zelanda 4
PT - Portogallo 4
RO - Romania 4
SN - Senegal 4
UG - Uganda 4
BH - Bahrain 3
BO - Bolivia 3
CL - Cile 3
GR - Grecia 3
IR - Iran 3
ME - Montenegro 3
MW - Malawi 3
NO - Norvegia 3
OM - Oman 3
PH - Filippine 3
TH - Thailandia 3
AF - Afghanistan, Repubblica islamica di 2
BG - Bulgaria 2
BJ - Benin 2
BS - Bahamas 2
BW - Botswana 2
CG - Congo 2
CR - Costa Rica 2
CW - ???statistics.table.value.countryCode.CW??? 2
GE - Georgia 2
GT - Guatemala 2
JM - Giamaica 2
LB - Libano 2
QA - Qatar 2
RS - Serbia 2
TJ - Tagikistan 2
UY - Uruguay 2
AO - Angola 1
BB - Barbados 1
BN - Brunei Darussalam 1
BY - Bielorussia 1
CI - Costa d'Avorio 1
GA - Gabon 1
Totale 25.816
Salva come PNG Salva come JPEG
Città #
Hong Kong 9.622
Ann Arbor 1.681
Chandler 838
Jacksonville 819
Singapore 754
Princeton 723
Woodbridge 520
Dallas 451
Ashburn 366
Wilmington 366
Houston 300
Beijing 244
Dublin 229
Dong Ket 217
Andover 164
Nanjing 146
Izmir 142
Pellezzano 128
Boardman 122
Los Angeles 95
Moscow 95
The Dalles 78
Munich 75
New York 69
Ho Chi Minh City 68
Salerno 64
Naples 57
Hebei 55
São Paulo 55
Shenyang 54
Ottawa 46
Changsha 45
Fairfield 45
Nanchang 42
Norwalk 42
Columbus 41
Jiaxing 39
Hanoi 34
Düsseldorf 33
Redwood City 33
Tokyo 33
Brooklyn 32
Montreal 29
Nuremberg 29
Tianjin 29
Jinan 28
Santa Clara 26
Turku 26
Washington 26
Mestre 25
Denver 24
Johannesburg 23
Belo Horizonte 22
Stockholm 22
Council Bluffs 21
Seattle 21
Falls Church 20
Guangzhou 20
London 20
Rio de Janeiro 20
Boston 19
Dearborn 19
Chennai 18
Warsaw 18
San Diego 17
Phoenix 16
Atlanta 15
Brasília 15
Chicago 15
Curitiba 15
Helsinki 15
Haiphong 14
Vienna 14
Lappeenranta 13
Nürnberg 13
Rome 13
San Francisco 13
Cambridge 12
Pune 12
Seoul 12
Zhengzhou 12
Amsterdam 11
Copenhagen 11
Dhaka 11
Mexico City 11
Fisciano 10
Frankfurt am Main 10
Ha Kwai Chung 10
Jakarta 10
Jinju 10
Milan 10
San Jose 10
San Mango Piemonte 10
Biên Hòa 9
Haikou 9
Maletto 9
Salvador 9
Ankara 8
Charlotte 8
Ribeirão Preto 8
Totale 19.987
Salva come PNG Salva come JPEG
Nome #
Transfer of innovation on allergic rhinitis and asthma multimorbidity in the elderly (MACVIA-ARIA) - EIP on AHA Twinning Reference Site (GARD research demonstration project) 940
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 736
Characterisation of asymptomatic patients and efficacy of preventive measures for SARS-CoV-2 infection in a large population of Southern Italy: a cohort study 718
Mucosal-Associated Invariant T Cells in T-Cell Non-Hodgkin Lymphomas: A Case Series 690
Non Alcoholic Fatty Liver: Epidemiology and Natural History 600
Impact of telaprevir in HCV patients with cirrhosis and RVR: Real-life data from boceprevir or telaprevir based “triple therapy” experience in southern Italy 583
Validation of the MASK-rhinitis visual analogue scale on smartphone screens to assess allergic rhinitis control 550
Forecasting Hepatitis C liver disease burden on real-life data. Does the hidden iceberg matter to reach the elimination goals? 505
Hepatitis C virus RNA in serum and liver histology in asymptomatic anti-HCV positive subjects. 479
Overview of prognostic systems for hepatocellular carcinoma and ITA.LI.CA external validation of MESH and CNLC classifications 410
Activation of fetal promoters of insulinlike growth factors II gene in hepatitis C virus-related chronic hepatitis, cirrhosis, and hepatocellular carcinoma. 397
Real-life glecaprevir/pibrentasvir in a large cohort of patients with hepatitis C virus infection: The MISTRAL Study 365
Hepatic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma 348
Hepatitis C virus infection in jail: Difficult-to-reach, not to-treat. Results of a point-of-care screening and treatment program 343
Prospective validation of the CLIP score: a new prognostic system for patient with cirrhosis and hepatocellular carcinoma 338
Management of the HBV reactivation in isolated HBcAb positive patients affected with Non Hodgkin Lymphoma. 329
Liver biopsy in type 2 diabetes mellitus: Steatohepatitis represents the sole feature of liver damage 299
The influence of acute lifestyle changes on NAFLD evolution in a multicentre cohort: a matter of body composition 295
Guidance to 2018 good practice: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma 292
442 TNF-alpha and IL-10 genetic polymorphisms influence the natural history and the response to antiviral therapy in HCV related chronic hepatitis 290
Alcoholic Hepatitis: Pathogenesis, Diagnosis and Treatment 273
A randomized controlled trial of pegylated interferon alpha-2a (40 KD) or interferon alpha-2a plus ribavirin and amantadine vs interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C. 271
18F-fluorodeoxyglucose positron emission tomography/computed tomography in the evaluation of early response in a primary hepatic lymphoma 269
Predicting de-novo portal vein thrombosis after HCV eradication: A long-term competing risk analysis in the ongoing PITER cohort 253
"Non alcoholic fatty liver disease and eNOS dysfunction in humans" 242
Efficacy and safety of new direct antiviral agents in HCV infected patients with Diffuse Large B Cell Non-Hodgkin Lymphoma 176
Sustained virological response by direct antiviral agents in HCV leads to an early and significant improvement of liver fibrosis 171
The diagnostic conundrum in non-alcoholic fatty liver disease 170
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis 169
Management of adults with paediatric-onset chronic liver disease: Strategic issues for transition care 168
Non-ulcer dyspepsia and Helicobacter pylori in type 2 diabetic patients: association with autonomic neuropathy. 158
A Long-term Treatment with Silybin in Patients with Non-alcoholic Steatohepatitis Stimulates Catalase Activity in Human Endothelial Cells 145
HIGH PREVALENCE OF HEPATITIS C (HCV) INFECTION AND FAVORABLE PROGNOSIS IN PRIMARY HEPATIC LYMPHOMA (PHL) 133
Association between non-alcoholic fatty liver disease, insulin resistance and Helicobacter pylori. 133
Insulin resistance and liver steatosis in chronic hepatitis C infection genotype 3 132
Efficacy and safety of glecaprevir/pibrentasvir in renally impaired patients with chronic HCV infection 132
Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon. 131
Coeliac disease and C virus-related chronic hepatitis: a non association 129
Endocan Serum Levels in Patients with Non-Alcoholic Fatty Liver Disease with or without Type 2 Diabetes Mellitus: A Pilot Study 128
Comparison of disease clusters in two elderly populations hospitalized in 2008 and 2010. 125
[629] THE INFLUENCE OF OBESITY AND DIABETES ON CLINICAL AND THERAPEUTICAL OUTCOME IN HCV RELATED CHRONIC HEPATITIS: AN ITALIAN NATIONWIDE SURVEY STUDY (PROBE GROUP) 123
Pharmacotherapy of alcoholic liver disease in clinical practice 122
[Hepatorenal syndrome. Clinical and pathogenetic aspects and therapeutic approach]. 119
Alcoholic Liver Disease and Hepatitis C Chronic Infection 118
Timed regulation of P-Element-Induced Wimpy Testis-interacting RNA expression during rat liver regeneration. 116
Untargeted metabolomics as a diagnostic tool in NAFLD: discrimination of steatosis, steatohepatitis and cirrhosis 116
Epidemiology and Natural History of Alcoholic Liver Disease 115
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data 111
507 The role of HBV occult infection in patients with non-hodgkin lymphoma: Prevalence and treatment options with nucleotide analogues 110
A controlled trial on treatment of patients with HCV infection and abnormal liver function tests with or without liver biopsy 108
The role of fructose in non-alcoholic steatohepatitis: Old relationship and new insights 107
Age-associated decline of hepatic handling of cholephilic anions in humans is reverted by S-adenosylmethionine (SAMe). 106
[Diabetic neuropathies. IV. Autonomous neuropathy. Peripheral sympathetic innervation and the cardiovascular system]. 106
The effect of antiviral therapy on hepatitis C virus-related thrombocytopenia: a case report. 106
Antiviral therapy: Why does it fail in HCV-related chronic hepatitis? 106
Ultrasound-guided fine needle aspiration biopsy of portal vein thrombosis in liver cirrhosis: results in 15 patients. 104
154 LOW RATE OF ONE-YEAR MORTALITY IN PATIENTS WITH STAGE 4 CIRRHOSIS: THE ITALIAN ASSOCIATION FOR THE STUDY OF LIVER (A.I.S.F.)-EPASCO PROSPECTIVE MULTICENTRE STUDY 104
Mortality risk according to different clinical characteristics of first episode of liver decompensation in cirrhotic patients: a nationwide, prospective, 3-year follow-up study in Italy. 103
Adiponectin in hepatology 103
A 15-Yr Prospective Histological Follow-Up Study in Patients With Persistently Normal Aminotransferase Levels (PNAL) Carrying HCV Infection. 102
Antiviral therapy after complete response to chemotherapy could be efficacious in HCV-positive non-Hodgkin's lymphoma. 100
A randomised controlled trial on pegylated interferon alfa-2a (40kd)(Pegasys) or IFN alfa-2a (ROFERON-A) plus ribavrin (RBV) and amantadine (AMA) vs IFN alfa-2a and RBV in naïve patients with chronic HCV 100
Risk factors for hospital readmission of elderly patients. 100
Chemical effect of bisphenol a on non-alcoholic fatty liver disease 100
Electrophysiological evidence for Na+-coupled bicarbonate transport in cultured rat hepatocytes 98
Occult hepatitis B virus infection in patients with non-Hodgkin lymphoma: the need for early diagnosis in anti-Hbc positive patients 98
Screening, Linkage to Care and Treatment of Hepatitis C Infection in Primary Care Setting in the South of Italy 98
478 Treating chronic hepatitis C in daily practice with PEG-IFN alfa2B and ribavirin. An Italian multicentre study 96
Helicobacter pylori infection but not small intestinal bacterial overgrowth may play a pathogenic role in rosacea 96
Vascular endothelial dysfunction in inflammatory bowel diseases: Pharmacological and nonpharmacological targets 96
Controversies about the histological features of chronic HCV patients with persistently normal alanine transaminase levels: what can be done about the present definition? 95
Corrigendum to "Antiviral therapy after complete response to chemotherapy could be efficacious in HCV-positive non-Hodgkin's lymphoma" [J Hepatol 49 (2008) 557-563] (DOI:10.1016/j.jhep.2008.06.025) 95
The aetiology of chronic hepatitis in Italy: results from a multicentre national study 93
Chitosan-coated liposomes loaded with butyric acid demonstrate anticancer and anti-inflammatory activity in human hepatoma HepG2 cells 92
Real-life effectiveness and safety of Glecaprevir/Pibrentasvir in HCV infected patients with chronic kidney disease 92
Color ultrasound-guided fine needle cutting biopsy for the characterization of diffuse liver damage in critical bone marrow transplanted patients. 91
A 3-ARM randomized study evaluating the efficacy of triple therapy of pegylated or recombinant interferon alpha-2a 3 MU both combined with ribavirin and amantadine versus dual therapy of recombinant interferon alpha-2a plus ribavirin in naive patients with chronic HCV hepatitis 90
Steatosis as a co-factor in chronic liver diseases 90
Genetic predictors of response to treatment of chronic hepatitis C virus infection in patients from southern Italy 90
Na+-H+ exchange activity in rat hepatocytes: Role in regulation of intracellular pH 88
93 HCV genotype 2 and 3 can be cured by PEG-IFN-alfa-2B and RBV for 12 wks: A randomized controlled study 88
Elevated expression and polymorphisms of SOCS3 influence patient response to antiviral therapy in chronic hepatitis C 87
Therapy expectations and physical comorbidity affect quality of life in chronic hepatitis C virus infection. 86
The epidemiology of non-alcoholic fatty liver disease and its connection with cardiovascular disease: Role of endothelial dysfunction 86
Etiology of newly-diagnosed cases of chronic liver disease in Southern Italy: Results of a prospective multicentric study 86
HCV antiviral therapy in injection drug users: difficult to treat or easy to cure? 86
Abnormal hepatic uptake of low doses of sulfobromophthalein in Gilbert's syndrome: the role of reduced affinity of the plasma membrane carrier of organic anions. 86
Steatohepatitis is associated with diabetes and fibrosis in genotype 1b HCV-related chronic liver disease 84
Retrospective, observational, multicentre study on an Italian population affected by chronic hepatitis C who failed to clear HCV-RNA after the combined therapy (PEG-IFN and ribavirin): NADIR study. 84
Impact of telaprevir in HCV patients with cirrhosis and RVR: real-life data from Boceprevir or Telaprevir based "triple therapy" experience in southern Italy 84
FN 44 HEPATIC RETINOL BINDING PROTEIN 4 (RBP-4) LEVELS ARE SIGNIFICANTLY RELATED TO THE STEATOHEPATITIS GRADE (COMPROMISSION) BUT NOT WITH HCV INFECTION 83
Regional distribution of transforming growth factor-alpha and epidermal growth factor in normal and portal hypertensive gastric mucosa in humans. 82
Familial clustering of heterogeneous chronic unconjugated hyperbilirubinemia. 82
Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. 82
Role of Oxidative Stress in Pathophysiology of Nonalcoholic Fatty Liver Disease 82
The role of bright liver echo pattern on ultrasound B-mode examination in the diagnosis of liver steatosis. 81
Hepatitis C virus carriers with persistently normal ALT levels: biological peculiarities and update of the natural history of liver disease at 10 years. 81
[Diabetic neuropathy. II. Autonomic neuropathy. The gastrointestinal system]. 81
Practice guidelines for the treatment of hepatitis C: recommendations from an AISF/SIMIT/SIMAST Expert Opinion Meeting. 81
The importance of HCV on burden of chronic liver disease in Italy: A multicenter prevalence study of 9,997 cases 81
Totale 18.791
Salva come PNG Salva come JPEG
Categoria #
all - tutte 84.457
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 84.457
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021805 0 0 0 0 0 52 160 13 135 12 180 253
2021/20221.248 6 3 8 6 26 24 34 58 193 169 156 565
2022/20232.009 207 118 63 237 291 430 12 185 301 5 108 52
2023/2024890 82 120 69 32 71 140 32 44 8 34 51 207
2024/20252.756 73 46 56 118 152 290 434 323 486 170 291 317
2025/202612.849 1.663 4.630 4.623 550 1.186 197 0 0 0 0 0 0
Totale 26.212